SUBSCRIBE
SUBSCRIBE

MASH

Pictured: 3D illustration of a damaged liver/iStoc
FDA
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.
March 18, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: Illustration of alphabetical letters ris
FDA
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
If you’re confused by the NASH versus MASH indication, you’re not alone.
March 15, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More
PRESS RELEASES
Press Releases
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
October 2, 2024
 · 
4 min read
Press Releases
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
October 2, 2024
 · 
1 min read
Press Releases
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 1, 2024
October 1, 2024
 · 
5 min read
Press Releases
New Published Data Show Reproducibility and Utility of Perspectum’s MRI in Patients With Metabolic Liver Disease
September 27, 2024
 · 
3 min read
Press Releases
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 25, 2024
 · 
4 min read
Press Releases
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
September 19, 2024
 · 
3 min read
Press Releases
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
September 13, 2024
 · 
4 min read
Press Releases
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
September 9, 2024
 · 
5 min read
Press Releases
Zealand Pharma Announces Financial Results for the First Half of 2024
August 15, 2024
 · 
12 min read
Press Releases
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
August 1, 2024
 · 
14 min read
Press Releases
Can-Fite Provides Namodenoson Patent Update
July 29, 2024
 · 
5 min read
Press Releases
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
July 26, 2024
 · 
12 min read
Load More